Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% vs CETROTIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Aminophylline is a complex of theophylline and ethylenediamine, acting as a phosphodiesterase inhibitor, increasing intracellular c AMP levels; nonselective adenosine receptor antagonist; enhances cardiac inotropy, bronchodilation, and CNS stimulation.
Cetrorelix is a synthetic decapeptide with gonadotropin-releasing hormone (Gn RH) antagonistic activity. It competitively blocks Gn RH receptors on the pituitary gland, reducing the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH).
Treatment of acute bronchospasm in asthma and COPD,Reversal of dipyridamole-induced adverse effects during stress testing,Apnea of prematurity (off-label),Status asthmaticus (off-label)
Inhibition of premature LH surges in women undergoing controlled ovarian stimulation for assisted reproductive technology (ART)
Loading dose: 5-6 mg/kg IV over 20-30 minutes, then continuous infusion: 0.5-0.7 mg/kg/hour IV.
0.25 mg subcutaneously once daily starting on day 7 of ovarian stimulation and continuing until the day of h CG administration.
Terminal elimination half-life is 6-12 hours in adults, 1-5 hours in children (due to faster clearance), 20-30 hours in premature neonates, and 10-15 hours in patients with hepatic cirrhosis or heart failure. Clinical context: dosing interval adjustment required based on half-life; prolonged half-life in hepatic impairment or cardiac decompensation increases risk of toxicity.
Terminal elimination half-life is approximately 36 hours after subcutaneous administration. This long half-life supports once-daily dosing for continuous Gn RH antagonist effect.
Hepatic via cytochrome P450 enzymes (CYP1A2, CYP3A4, CYP2E1); saturable kinetics; extensive first-pass metabolism.
Cetrorelix is metabolized via peptidase cleavage and is primarily eliminated unchanged in urine and feces.
Renal excretion of unchanged theophylline (10-20%) and metabolites (80-90%). In neonates, renal excretion of unchanged drug is higher (up to 50%). Biliary/fecal excretion is negligible.
Primarily renal excretion of unchanged drug (approx. 40-50%) and metabolites; remainder excreted in feces via biliary elimination. Total recovery in urine and feces accounts for >90% of dose.
Approximately 40% bound to plasma proteins, mainly albumin. In neonates, preterm infants, and patients with hepatic cirrhosis, protein binding is reduced (free fraction increases). Binding is also saturable at high theophylline concentrations.
Approximately 80% bound to plasma proteins, primarily albumin.
Volume of distribution is approximately 0.45 L/kg (range 0.3-0.7 L/kg) in adults. In neonates, Vd is larger (~0.6-0.8 L/kg). Clinical meaning: Vd indicates extensive distribution into body water; loading doses are calculated using Vd (e.g., 1 mg/kg raises serum concentration by ~2 mcg/m L).
Approximately 0.7 L/kg, indicating distribution primarily into extracellular fluid and limited tissue binding.
Oral immediate-release: 100% (well absorbed). Rectal: 80-100% (absorption may be erratic). IV: 100%. No significant first-pass metabolism.
Subcutaneous administration: approximately 85% absolute bioavailability compared to intravenous injection.
No specific dose adjustment required for GFR >10 m L/min. For GFR <10 m L/min, reduce infusion rate by 50%.
No specific dose adjustment is recommended for patients with renal impairment; however, caution is advised in severe impairment due to limited data.
Child-Pugh Class A: reduce dose by 25%; Class B: reduce dose by 50%; Class C: reduce dose by 75%.
No specific dose adjustment is recommended for patients with hepatic impairment; however, caution is advised in severe impairment due to limited data.
Loading dose: 5-6 mg/kg IV over 20-30 minutes; continuous infusion: 0.5-0.7 mg/kg/hour (age-dependent, with lower doses for younger children).
Not indicated for pediatric use; safety and efficacy have not been established.
Elderly patients may have reduced clearance; consider starting at the lower end of dosing range (e.g., 0.3-0.5 mg/kg/hour) and titrate based on serum levels.
Not indicated for geriatric use; safety and efficacy have not been established in women over 65 years.
Theophylline toxicity is dose-related and can be fatal; monitor serum theophylline levels closely; use with caution in patients with risk factors for reduced clearance (e.g., hepatic impairment, heart failure, elderly).
None.
Narrow therapeutic index; severe toxicity can occur at levels >20 mcg/m L,Seizures and arrhythmias may occur without preceding symptoms,Variable clearance due to drug interactions, disease states, age, and smoking,Use with caution in peptic ulcer disease, seizure disorders, hyperthyroidism, and cardiac disease
Hypersensitivity reactions (e.g., anaphylaxis) have been reported.,Ovarian hyperstimulation syndrome (OHSS) may occur; monitor during stimulation.,Use caution in patients with active allergic conditions or history of asthma.
Hypersensitivity to aminophylline or any component,Hypersensitivity to theophylline or ethylenediamine,Cardiac arrhythmias requiring immediate therapy (relative)
Hypersensitivity to cetrorelix, Gn RH, or any other Gn RH analog.,Known or suspected pregnancy.,Breastfeeding.,Severe renal impairment (creatinine clearance <30 m L/min).,Pre-existing moderate to severe hepatic impairment.
Avoid high-dose caffeine (coffee, tea, energy drinks, chocolate) as it may increase risk of side effects like nausea, anxiety, and tachycardia. Charcoal-broiled foods and a high-protein diet may increase theophylline clearance. Consistent dietary intake is recommended.
No known food interactions. No dietary restrictions required.
First trimester: Limited data; no increased risk of major malformations observed in human studies. Second and third trimesters: Risk of fetal tachycardia and jitteriness with high maternal doses; may cause transient neonatal tachycardia with chronic use. No documented teratogenicity.
Pregnancy Category X. Cetrorelix is contraindicated during pregnancy due to risk of fetal harm. In animal studies, it caused embryolethality and teratogenicity at doses lower than human exposure. No adequate human studies exist.
Aminophylline/theophylline is excreted into breast milk with an M/P ratio of approximately 0.6-0.7. Infant exposure is low (about 1-10% of maternal dose). Irritability and insomnia reported rarely. Use with caution, monitor infant for signs of theophylline toxicity.
No data on cetrorelix excretion in human milk. M/P ratio unknown. Given its peptide nature and short half-life, excretion is unlikely but not confirmed. Caution advised; avoid use in nursing mothers unless clearly needed.
Pregnancy decreases theophylline clearance by approximately 20-30% during third trimester. Dosing adjustments may be required: monitor serum levels and adjust dose to maintain therapeutic levels. Postpartum clearance returns rapidly, requiring downward dose adjustment.
Cetrorelix is contraindicated in pregnancy; no dosing adjustments apply. Dose modifications are not recommended as drug should not be used.
Aminophylline is a bronchodilator that releases theophylline. Monitor serum theophylline levels (therapeutic range 5-15 mcg/m L). Avoid in patients with active peptic ulcer disease, seizure disorders, or hypersensitivity to xanthines. Caution in hepatic impairment, heart failure, and elderly due to reduced clearance. Drug interactions with cimetidine, ciprofloxacin, and macrolides increase theophylline levels.
Cetrotide (cetrorelix) is a Gn RH antagonist used in controlled ovarian stimulation to prevent premature LH surges. Administer subcutaneously in the lower abdominal wall; rotate sites. Monitor for ovarian hyperstimulation syndrome (OHSS). Onset of action is immediate; does not cause flare effect like Gn RH agonists. Dose adjustment not required in renal or hepatic impairment. Use with caution in patients with allergies to Gn RH analogs or mannitol.
Do not exceed prescribed dose. Take exactly as directed.,Avoid caffeine-containing products (coffee, tea, cola, chocolate) as they may increase side effects.,Report symptoms of toxicity: nausea, vomiting, insomnia, rapid heart rate, palpitations, or seizures.,Do not crush or chew extended-release forms; take with food if gastric upset occurs.,Do not stop abruptly without consulting your healthcare provider.
Inject exactly as prescribed, at the same time each day during the stimulation cycle.,Do not skip doses; missing a dose may increase risk of premature ovulation.,Report any signs of allergic reaction, such as rash, hives, or difficulty breathing.,Mild injection site reactions (redness, swelling, itching) are common and usually resolve.,Avoid pregnancy prior to the procedure; use non-hormonal contraception if needed.,Understand the risk of OHSS: symptoms include severe pelvic pain, nausea, vomiting, sudden weight gain, and decreased urination.
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% vs CETROTIDE, answered by our medical review team.
AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is a Electrolyte that works by Aminophylline is a complex of theophylline and ethylenediamine, acting as a phosphodiesterase inhibitor, increasing intracellular c AMP levels; nonselective adenosine receptor antagonist; enhances cardiac inotropy, bronchodilation, and CNS stimulation.. CETROTIDE is a GnRH antagonist that works by Cetrorelix is a synthetic decapeptide with gonadotropin-releasing hormone (Gn RH) antagonistic activity. It competitively blocks Gn RH receptors on the pituitary gland, reducing the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH).. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% and CETROTIDE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is: Loading dose: 5-6 mg/kg IV over 20-30 minutes, then continuous infusion: 0.5-0.7 mg/kg/hour IV.. The standard adult dose of CETROTIDE is: 0.25 mg subcutaneously once daily starting on day 7 of ovarian stimulation and continuing until the day of h CG administration.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% and CETROTIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is classified as Category A/B. First trimester: Limited data; no increased risk of major malformations observed in human studies. Second and third trimesters: Risk of fetal tachycardia and jitteriness with high . CETROTIDE is classified as Category C. Pregnancy Category X. Cetrorelix is contraindicated during pregnancy due to risk of fetal harm. In animal studies, it caused embryolethality and teratogenicity at doses lower than . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.